Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of rivastigmine with glycopyrrolate or trospium in healthy elderly volunteers
NL-OMON44454Phase 1Active, not recruiting
- Sponsor
- Sio Gene Therapies
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of rivastigmine, glycopyrronium and trospium in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) (2 arms), sponsored by Sio Gene Therapies. Primary endpoints: Number of subjects completing full dose escalation and Number of subjects completing the 6 mg BID dosing period. Started Jul 2017; status: active, not recruiting.
02
Drugs
rivastigmineglycopyrroniumtrospium
03
Conditions
Alzheimer's disease (AD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NL-OMON44454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44454.